EdgeRx vs Henry Meds
Two GLP-1 desks, one scoreboard. We put EdgeRx and Henry Meds head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Too close to call on the Brief Score.
EdgeRx and Henry Meds are level at 84/100. The scores won't separate them, so the pick comes down to fit: EdgeRx for men who want a straightforward, disclosed weekly-injectable price on either molecule and value knowing the pharmacy filling the script by name. Henry Meds for readers who want a simple, well-known flat-fee program and don't mind paying up for it.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| EdgeRx | Henry Meds | |
|---|---|---|
| Brief Score | 84/100 (B) | 84/100 (B) |
| Semaglutide | $229/mo injectable | $249/mo |
| Tirzepatide | $299/mo injectable | $349/mo |
| Coverage | 46 states (excludes Arkansas, Indiana, Minnesota, South Carolina) | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Risingprice rising |
EdgeRx: First reading — flat weekly-injectable pricing on both molecules, named CMA and named 503A pharmacy.
Henry Meds: Flat-fee pioneer, but its line has drifted to the higher end of the tracker.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.